In order to remain dedicated to its main cash cow--vaccines--Inovio ($INO) is making some changes. This week, the company's VGX Animal Health subsidiary sold its animal health assets--including an exclusive license with Inovio for animal DNA vaccines--to South Korea's Plumbline Life Sciences. Inovio will instead stay "sharply focused" on the company's immunotherapy products, President and CEO Dr. J. Joseph Kim said in a statement. Release